Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production ...

Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

Eli Lilly said on Wednesday it is partnering with Walmart to expand access to Lilly's weight-loss drug Zepbound, which will ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

Eli Lilly said on Tuesday it was collaborating with Nvidia to build a supercomputer to help with drug discovery and shorten ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

During the industry’s onshoring rush of the last nine months, Eli Lilly has been among the most aggressive biopharma compa | Eli Lilly is allotting $3 billion to establish an oral medicines ...

While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.

A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.